Conference Reports for NATAP

64rd Annual Meeting of the American Association for the Study of Liver Diseases Washington, DC Nov 1-5 2013 Back

SVR results of a once-daily regimen of simeprevir (SMV, TMC435) plus sofosbuvir (SOF, GS-7977) with or without ribavirin in cirrhotic and non-cirrhotic HCV genotype 1 treatment-naïve and prior null responder patients: The COSMOS study       Reported by Jules Levin AASLD 2013 Nov 1-4 Wash DC   Ira M Jacobson,1 Reem Ghalib,2 Maribel Rodriguez-Torres,3 Zobair M Younossi,4 Ana Corregidor,5 Mark S Sulkowski,6 Edwin DeJesus,7 Brian Pearlman,8 Mordechai Rabinovitz,9 Norman Gitlin,10 Joseph K Lim,11 Paul J Pockros,12 Bart Fevery,13 Tom Lambrecht,14 Sivi Ouwerkerk-Mahadevan,13 Katleen Callewaert,13 William T Symonds,15 Gaston Picchio,16 Karen Lindsay,17 Maria Beumont-Mauviel,13 Eric Lawitz18 1Weill Cornell Medical College, New York, NY, USA; 2Medicine and Gastroenterology and Hepatology, The Liver Institute, Dallas, TX, USA; 3Fundación de Investigación, San Juan, Puerto Rico, USA; 4Department of Medicine, Inova Fairfax Hospital, Falls Church, VA, USA; 5Borland-Groover Clinic, 4800 Belfort Rd, Jacksonville, FL, USA; 6Johns Hopkins University School of Medicine, Baltimore, MD, USA; 7Orlando Immunology Center, Orlando, FL, USA; 8Atlanta Medical Center, Atlanta, GA, USA; 9University of Pittsburgh Medical Center, Pittsburgh, PA, USA; 10Atlanta Gastroenterology Association, Atlanta, GA, USA; 11Yale University School of Medicine, New Haven, CT, USA; 12Scripps Clinic, La Jolla, CA, USA; 13Janssen Research & Development, Beerse, Belgium; 14Novellas Healthcare, Zellik, Belgium; 15Gilead Sciences Inc, Foster City, CA, USA; 16Janssen Research & Development, Titusville, NJ; 17Hepatitis C Consulting, LLC, Philadelphia, PA; 18The Texas Liver Institute, Univ. of Texas Health Science Center, San Antonio, TX, USA